Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Moinzadeh, Pia ^a,b   Fonseca, Carmen ^a   Hellmich, Martin ^b   Shah, Ami A ^c   Chighizola, Cecilia ^a,d   Denton, Christopher P ^a   Ong, Voon H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; RNA POLYMERASE II; RNA POLYMERASE II ANTIBODY; SCL 70 ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIGEN; DNA DIRECTED RNA POLYMERASE III;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; COUNTER IMMUNOELECTROPHORESIS; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC CANCER; HAZARD RATIO; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; LABORATORY TEST; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MIDDLE AGED; PREDICTIVE VALUE; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SCLERODERMA; SYSTEMIC SCLEROSIS; TERTIARY CARE CENTER; UNITED KINGDOM; AGED; BLOOD; COMPLICATION; IMMUNOLOGY; NEOPLASMS; RISK FACTOR;

ADULT; AGED; AUTOANTIBODIES; AUTOANTIGENS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 84897517521     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4486     Document Type: Article

References (46)

1. Wooten M. Systemic sclerosis and malignancy:a review of the literature. South Med J 2008, 101:59-62. 10.1097/SMJ.0b013e31815838ce, 18176294.
2. Colaci M, Giuggioli D, Sebastiani M, Manfredi A, Vacchi C, Spagnolo P, Cerri S, Luppi F, Richeldi L, Ferri C. Lung cancer in scleroderma:results from an Italian rheumatologic center and review of the literature. Autoimmun Rev 2013, 12:374-379. 10.1016/j.autrev.2012.06.003, 22743031.
3. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993, 36:460-464. 10.1002/art.1780360405, 8457221.
4. Hashimoto A, Arinuma Y, Nagai T, Tanaka S, Matsui T, Tohma S, Endo H, Hirohata S. Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis. Intern Med 2012, 51:1683-1688. 10.2169/internalmedicine.51.7686, 22790126.
5. Marasini B, Conciato L, Belloli L, Massarotti M. Systemic sclerosis and cancer. Int J Immunopathol Pharmacol 2009, 22:573-578.
6. Szekanecz T, Szamosi S, Horváth T, Németh T, Juhász B, Szántó J, Szücs G, Szekanecz Z. Malignancies associated with systemic sclerosis. Autoimmun Rev 2012, 11:852-855. 10.1016/j.autrev.2012.02.021, 22410174.
7. Airò P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011, 38:1329-1334. 10.3899/jrheum.101144, 21459934.
8. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010, 62:2787-2795. 10.1002/art.27549, 2946521, 20506513.
9. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M, Igarashi A, Sogame R, Hashimoto T, Koga T, Nishino A, Ishiguro N, Sugimoto N, Aoki R, Ando N, Abe T, Kanda T, Kuwana M, Takehara K, Fujimoto M. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies:possible association with malignancy. Ann Rheum Dis 2012, 71:710-713. 10.1136/annrheumdis-2011-200697, 22258483.
10. Trallero-Araguás E, Labrador-Horrillo M, Selva-O'Callaghan A, Martínez MA, Martínez-Gómez X, Palou E, Rodriguez-Sanchez JL, Vilardell-Tarrés M. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010, 89:47-52. 10.1097/MD.0b013e3181ca14ff, 20075704.
11. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis):classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
12. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
14. Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, Denton CP. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis:application of a latent linear trajectory model. Arthritis Rheum 2007, 56:2422-2431. 10.1002/art.22721, 17599771.
15. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010, 6:112-116. 10.1038/nrrheum.2009.238, 20125179.
16. Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP. A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology (Oxford) 2009, 48:1218-1221. 10.1093/rheumatology/kep215, 19696067.
17. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42. 10.1016/j.semarthrit.2005.03.005, 16084222.
18. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP. Scleroderma renal crisis:patient characteristics and long-term outcomes. QJM 2007, 100:485-494. 10.1093/qjmed/hcm052, 17601770.
19. Statistics with Confidence:Confidence Intervals and Statistical Guidelines 2000, Chichester, UK:Wiley-Blackwell/BMJ Books, Altman D, Machin D, Bryant T, Gardner S, 2.
20. Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A. Systemic sclerosis (scleroderma) and cancer risk:systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2013, 52:143-154. 10.1093/rheumatology/kes303, 23175568.
21. Launay D, Le Berre R, Hatron PY, Peyrat JP, Hachulla E, Devulder B, Hebbar M. Association between systemic sclerosis and breast cancer:eight new cases and review of the literature. Clin Rheumatol 2004, 23:516-522. 10.1007/s10067-004-0940-5, 15801071.
22. Levine SM. Cancer and myositis:new insights into an old association. Curr Opin Rheumatol 2006, 18:620-624. 10.1097/01.bor.0000245721.02512.77, 17053509.
23. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005, 52:1481-1490. 10.1002/art.21029, 15880596.
24. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis:a population-based study. Lancet 2001, 357:96-100. 10.1016/S0140-6736(00)03540-6, 11197446.
25. Chen W, Böcker W, Brosius J, Tiedge H. Expression of neural BC200 RNA in human tumours. J Pathol 1997, 183:345-351. 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8, 9422992.
26. Felton-Edkins ZA, White RJ. Multiple mechanisms contribute to the activation of RNA polymerase III transcription in cells transformed by papovaviruses. J Biol Chem 2002, 277:48182-48191. 10.1074/jbc.M201333200, 12370195.
27. Larminie CG, Sutcliffe JE, Tosh K, Winter AG, Felton-Edkins ZA, White RJ. Activation of RNA polymerase III transcription in cells transformed by simian virus 40. Mol Cell Biol 1999, 19:4927-4934. 84300, 10373542.
28. White RJ. RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol 2005, 6:69-78. 10.1038/nrm1551, 15688068.
29. Kenneth NS, Ramsbottom BA, Gomez-Roman N, Marshall L, Cole PA, White RJ. TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. Proc Natl Acad Sci U S A 2007, 104:14917-14922. 10.1073/pnas.0702909104, 1986588, 17848523.
30. Domsic RT, Medsger TA. Disease subsets in clinical practice. Scleroderma:From Pathogenesis to Comprehensive Management 2012, 45-52. New York:Springer, Varga J, Denton CP, Wigley FM.
31. Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol 2012, 43:249-255. 10.1007/s12016-012-8331-1, 22711501.
32. Rosenthal AK, McLaughlin JK, Gridley G, Nyrén O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995, 76:910-914. 10.1002/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T, 8625197.
33. Roumm AD, Medsger TA. Cancer and systemic sclerosis:an epidemiologic study. Arthritis Rheum 1985, 28:1336-1340. 10.1002/art.1780281204, 4084328.
34. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T. Lung cancer associated with several connective tissue diseases:with a review of literature. Rheumatol Int 2001, 21:106-111. 10.1007/s00296-001-0141-3, 11765223.
35. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985, 12:1136-1139.
36. Halpert RD, Laufer I, Thompson JJ, Feczko PJ. Adenocarcinoma of the esophagus in patients with scleroderma. AJR Am J Roentgenol 1983, 140:927-930. 10.2214/ajr.140.5.927, 6601435.
37. Katzka DA, Reynolds JC, Saul SH, Plotkin A, Lang CA, Ouyang A, Jimenez S, Cohen S. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med 1987, 82:46-52. 10.1016/0002-9343(87)90376-7, 3799692.
38. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma:a population based cohort study. Ann Rheum Dis 2003, 62:728-731. 10.1136/ard.62.8.728, 1754624, 12860727.
39. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis:meta-analysis of population-based cohort studies. Arthritis Rheum 1913-1921, 2013:65.
40. Forbes AM, Woodrow JC, Verbov JL, Graham RM. Carcinoma of breast and scleroderma:four further cases and a literature review. Br J Rheumatol 1989, 28:65-69. 10.1093/rheumatology/28.1.65, 2537127.
41. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 2001, 19:197-200.
42. Mirone L, Barini A. Androgen and prolactin (Prl) levels in systemic sclerosis (SSc):relationship to disease severity. Ann NY Acad Sci 2006, 1069:257-262. 10.1196/annals.1351.023, 16855152.
43. Straub RH, Zeuner M, Lock G, Schölmerich J, Lang B. High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br J Rheumatol 1997, 36:426-432. 10.1093/rheumatology/36.4.426, 9159534.
44. López-Marure R, Contreras PG, Dillon JS. Effects of dehydroepiandrosterone on proliferation, migration, and death of breast cancer cells. Eur J Pharmacol 2011, 660:268-274. 10.1016/j.ejphar.2011.03.040, 21497598.
45. Qian N, Ueno T. Is dysfunction of caveolin-1 a link between systemic sclerosis and breast cancer, opening a window on both etiologies?. Arch Med Res 2010, 41:297-301. 10.1016/j.arcmed.2010.05.009, 20637375.
46. Lei W, Luo Y, Lei W, Luo Y, Yan K, Zhao S, Li Y, Qiu X, Zhou Y, Long H, Zhao M, Liang Y, Su Y, Lu Q. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 2009, 38:369-374. 10.1080/03009740902758875, 19444718.